BTIG Maintains Buy on Guardant Health, Raises Price Target to $160

Benzinga Newsdesk www.benzinga.com Positive 81.9%

Neg 0% Neu 0% Pos 81.9%

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $155 to $160.